ReviewPhytotherapy research : PTR2022
Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.
Review in Phytotherapy research : PTR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Trial
- Bioactive Phytochemicals: Unlocking the Promise of Natural Remedies for Diabetes Mellitus.Current pharmaceutical biotechnology · 2026Review
- A review on the role of functional foods and derivatives for diabetes management.Journal of food science and technology · 2025Review
- Phylogeny, ethnomedicinal use and the distribution of phytoestrogens in the Fabaceae.Frontiers in pharmacology · 2025Article
- Assessing the efficacy of herbal supplements for managing obesity: A comprehensive review of global clinical trials.Iranian journal of basic medical sciences · 2025Review
- Potential Human Health Benefits ofNutrients · 2024Article
- Purification and Characterization of Proteinaceous Thermostable α-Amylase Inhibitor from Sardinian Common Bean Nieddone Cultivar (Plants (Basel, Switzerland) · 2024Article
- Comparative Analysis of Phytochemical Profiles and Selected Biological Activities of Various Morphological Parts ofMolecules (Basel, Switzerland) · 2024Article
- Biochemical and Phylogenetic Analysis of ItalianPlants (Basel, Switzerland) · 2023Article
- Plant Toxic Proteins: Their Biological Activities, Mechanism of Action and Removal Strategies.Toxins · 2023Review
- A review on anti-nutritional factors: unraveling the natural gateways to human health.Frontiers in nutrition · 2023Review
- Antiadipogenic and antiobesogenic effects of pterostilbene in 3T3-L1 preadipocyte models.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Common bean (Phaseolus vulgaris L.) α-amylase inhibitors as safe nutraceutical strategy against diabetes and obesity: An update review.Phytotherapy research : PTR · 2022Review
- Metabolites extracted from microorganisms as potential inhibitors of glycosidases (α-glucosidase and α-amylase): A review.Frontiers in microbiology · 2022Review
- Antinutritional factors, nutritional improvement, and future food use of common beans: A perspective.Frontiers in plant science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overweight and obesity are constantly increasing, not only in Western countries but also in low-middle-income ones. The decrease of both the intake of carbohydrates and their assimilation are among the main dietary strategies to counter these conditions. α-Amylase, a key enzyme involved in the digestion of carbohydrates, is the target enzyme to reduce the absorption rate of carbohydrates. α-Amylase inhibitors (α-AIs) can be found in plants. The common bean, Phaseolus vulgaris is of particular interest due to the presence of protein-based α-AIs which, through a protein-protein interaction, reduce the activity of this enzyme. Here we describe the nature of the various types of common bean seed extracts, the type of protein inhibitors they contain, reviewing the recent Literature about their molecular structure and mechanism of action. We also explore the existing evidence (clinical trials conducted on both animals and humans) supporting the potential benefits of this protein inhibitors from P. vulgaris, also highlighting the urgent need of further studies to confirm the clinical efficacy of the commercial products. This work could contribute to summarize the knowledge and application of P. vulgaris extract as a nutraceutical strategy for controlling unwanted weight gains, also highlighting the current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.